Axsome Therapeutics, Inc. (NASDAQ:AXSM) is Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s 4th Largest Position

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. grew its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 746.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 285,494 shares of the company's stock after purchasing an additional 251,775 shares during the quarter. Axsome Therapeutics comprises about 6.7% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s holdings, making the stock its 4th biggest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned about 0.58% of Axsome Therapeutics worth $33,297,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its holdings in shares of Axsome Therapeutics by 16,852.7% in the first quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock worth $73,176,000 after buying an additional 623,717 shares during the last quarter. Boxer Capital Management LLC purchased a new position in Axsome Therapeutics during the fourth quarter valued at approximately $39,767,000. Lazard Asset Management LLC lifted its holdings in Axsome Therapeutics by 525.7% during the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after purchasing an additional 451,737 shares in the last quarter. Norges Bank purchased a new position in Axsome Therapeutics during the fourth quarter valued at approximately $34,100,000. Finally, BVF Inc. IL lifted its holdings in Axsome Therapeutics by 32.7% during the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AXSM has been the topic of several research analyst reports. Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a report on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 target price on the stock. Robert W. Baird boosted their price target on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Jefferies Financial Group assumed coverage on shares of Axsome Therapeutics in a research report on Monday, April 7th. They issued a "buy" rating and a $200.00 price target on the stock. Finally, Royal Bank Of Canada cut their price objective on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a research report on Thursday, June 12th. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Axsome Therapeutics currently has an average rating of "Buy" and a consensus target price of $172.33.

Insider Buying and Selling

In other news, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the transaction, the director owned 50,387 shares of the company's stock, valued at approximately $5,314,316.89. The trade was a 6.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Mark L. Jacobson sold 25,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the completion of the transaction, the chief operating officer directly owned 5,783 shares in the company, valued at $638,674.52. The trade was a 81.21% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,437 shares of company stock valued at $9,834,215. 22.30% of the stock is owned by corporate insiders.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM traded down $4.08 during trading on Tuesday, hitting $105.61. 326,312 shares of the stock traded hands, compared to its average volume of 664,571. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. The company has a market cap of $5.20 billion, a price-to-earnings ratio of -18.24 and a beta of 0.46. The company has a fifty day moving average price of $106.54 and a two-hundred day moving average price of $109.63. Axsome Therapeutics, Inc. has a 52-week low of $72.21 and a 52-week high of $139.13.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.